As preventive clinical trials have increasingly focused on individuals in the earliest preclinical phases of AD, our results highlight that the selection of CU individuals Aβ+/Ast+ without overt p-tau abnormality may offer a time window very early in the disease process but with increased risk of AD-related progression. Here, MAPT is linked to Alzheimer disease.